Core Viewpoint - Broadwood Partners, L.P. and its affiliates, owning 30.2% of STAAR Surgical Company's outstanding common stock, oppose the proposed sale of the Company to Alcon Inc. on unchanged transaction terms following a flawed process [1] Group 1 - Broadwood Partners holds a significant stake of 30.2% in STAAR Surgical Company [1] - The proposed sale to Alcon Inc. is being contested by Broadwood due to concerns over the transaction terms [1] - The process leading to the proposed sale has been described as flawed by Broadwood [1]

Core Viewpoint - Broadwood Partners and its affiliates announced that Egan-Jones Ratings Company has reaffirmed its recommendation for shareholders to vote "AGAINST" the proposed acquisition of STAAR Surgical Company by Alcon Inc. [1] Group 1 - Egan-Jones Ratings Company is a leading proxy advisory firm [1] - The recommendation is to vote against the acquisition on the GREEN Proxy Card [1] - The announcement follows STAAR's completion of a 30-day go-shop period [1]

Core Points - STAAR Surgical has amended its merger agreement with Alcon to allow a 30-day go-shop period for soliciting third-party proposals, aiming to maximize stockholder value [1][2][3] - Alcon has waived its matching rights and information rights during this go-shop period, facilitating a more open solicitation process [3][4] - The Special Meeting of Stockholders to vote on the merger proposal has been postponed to December 19, 2025, to allow time for potential third-party proposals [4] Summary by Sections Merger Agreement Amendments - The new go-shop period allows STAAR to actively seek third-party proposals until December 6, 2025 [3] - Alcon has waived matching rights for any superior proposals made during this period [3] - STAAR is not obligated to inform Alcon about any bids received until the go-shop period ends, promoting a fair solicitation process [3] Stockholder Engagement - STAAR's CEO emphasized the commitment to maximizing stockholder value and the potential benefits of the go-shop process [2] - Alcon will engage with STAAR stockholders to garner support for the merger proposal [2][4] Special Meeting of Stockholders - The Special Meeting originally scheduled for December 3, 2025, has been postponed to December 19, 2025, allowing stockholders to consider any new proposals [4]

Core Viewpoint - Broadwood Partners, L.P. and its affiliates are opposing Alcon Inc.'s proposed acquisition of STAAR Surgical Company, urging shareholders to vote against the transaction using their GREEN Proxy Card [1] Group 1: Company Actions - Broadwood Partners owns 27.5% of STAAR's outstanding common stock, indicating significant influence over shareholder decisions [1] - The firm continues to actively communicate its stance against the acquisition, highlighting its commitment to protecting shareholder interests [1] Group 2: Market Implications - The opposition from a major shareholder like Broadwood could impact the outcome of the acquisition vote, potentially leading to a reevaluation of the proposed transaction by Alcon [1]

Core Viewpoint - Alcon has released investor discussion materials that emphasize the value of its merger proposal for STAAR stockholders, aiming to strengthen its position in the market [1] Group 1: Merger Proposal - The merger proposal is positioned as beneficial for STAAR stockholders, highlighting potential value creation [1] - Alcon's materials provide detailed insights into the strategic advantages of the merger, including enhanced market presence and operational synergies [1] Group 2: Investor Communication - The release of discussion materials is part of Alcon's broader strategy to engage with investors and clarify the benefits of the proposed merger [1] - Alcon aims to address any concerns from STAAR stockholders regarding the merger, reinforcing its commitment to transparency and shareholder value [1]

Core Viewpoint - Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, has expressed its concerns regarding the adjournment of STAAR's Special Meeting of Stockholders to vote on the proposed sale to Alcon Inc. [1] Group 1 - Yunqi Capital Limited is an investment management firm that advises funds and holds a significant stake in STAAR Surgical Company [1] - The decision to adjourn the Special Meeting of Stockholders was made by STAAR Surgical and Alcon Inc. [1] - The proposed sale to Alcon was initially announced in August [1]

Core Points - Alcon and STAAR Surgical have agreed to adjourn STAAR's Special Meeting of Stockholders originally scheduled for October 23, 2025, in relation to their merger agreement [1][2] - The new date for the Special Meeting is set for November 6, 2025, at 8:30 a.m. Pacific Time, with the record date for eligible stockholders remaining September 12, 2025 [2] Company Information - Alcon is a global leader in eye care with over 75 years of experience, offering a wide range of products that enhance sight and improve lives, impacting over 260 million people annually in more than 140 countries [3] - STAAR Surgical specializes in implantable phakic intraocular lenses, providing vision correction solutions that reduce or eliminate the need for glasses or contact lenses, with over 3 million ICLs sold in more than 75 countries [4]

Core Viewpoint - Broadwood Partners, L.P. intends to call a Special Meeting of STAAR Surgical Company shareholders to remove several directors, indicating potential governance issues within the company [1]. Group 1 - Broadwood Partners owns 27.5% of the outstanding common stock of STAAR Surgical Company [1]. - The notification to the Board of Directors was made yesterday, highlighting the urgency of the situation [1]. - Neal C. Bradsher, the Founder and President of Broadwood, confirmed the intention to call the Special Meeting [1].

Core Viewpoint - Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, opposes the proposed sale of STAAR to Alcon Inc. on the terms announced on August 5, 2025 [1] Group 1 - Yunqi Capital has issued a letter to the Board of Directors of STAAR expressing its opposition to the sale [1] - The opposition is based on the terms of the sale proposed to Alcon Inc. [1]

Summary of Key Points from the Expert Call on China's Ophthalmology Market Industry Overview - **Industry**: China's Ophthalmology Market - **Key Event**: Congress of Chinese Ophthalmological Society (CCOS) held in September 2025 Core Insights 1. **Market Dynamics**: The expert highlighted several key topics discussed during the CCOS, including the launch of new technologies and the current state of various ophthalmology segments [1][2][7] 2. **Business Pressure**: The ophthalmology segment faced significant pressure in Q3, with salary cuts and declining surgery volumes being major concerns among ophthalmologists [2][7] 3. **Refractive Surgery Trends**: - Surgery volume saw a decline in July and August after decent demand in June - Prices for refractive surgeries, particularly SMILE, are on a downward trend due to increased competition and new technology [2][10][20] 4. **Cataract Surgery**: - Q3 typically experiences low surgery volumes, exacerbated by hot weather and strict market screening controls by private hospitals [2][8] 5. **Optometry Demand**: Demand for optometry services was strong only during specific periods, such as the start of summer holidays and the new semester [2][9] Pricing and Competition 6. **Pricing Trends**: - The price of SMILE 3.0 has been reduced to RMB 9,800, while the price for SMILE 4.0 is set at RMB 16,800 but has not been firmly established in hospitals [7][10] - Public hospitals are expected to cut prices for OK lenses due to competition [20] 7. **High-End Intraocular Lenses (IOLs)**: - The market for high-end IOLs is limited, with concerns over the materials used in newer products [11][14] - Eyebright's EDOF IOL was recently approved, but its market potential remains uncertain [13] Industry Challenges 8. **Insurance Funding Control**: Tighter control over basic medical insurance (BMI) funding has been noted, with stricter requirements compared to the previous year [21] 9. **Hospital Closures**: Approximately 50% of eye hospitals have closed in recent years, with another 30% expected to close in the next three to five years [16] 10. **Competitive Landscape**: Large hospital chains are becoming more competitive, leveraging procurement advantages over smaller hospitals [17] Alcon's Acquisition of STAAR 11. **Acquisition Challenges**: Alcon's proposed acquisition of STAAR is viewed as challenging, with major shareholders expressing concerns over the low offering price [3][18] 12. **Potential Impact**: If successful, Alcon may enhance doctor training and marketing efforts for ICL, although it faces challenges in marketing compared to competitors like Carl Zeiss [19] Future Outlook 13. **Market Potential**: The potential launch of new SMILE equipment by domestic companies in 2026 could lead to significant price reductions through group purchasing organizations (GPOs) [22] 14. **Regulatory Risks**: The healthcare industry faces risks including unexpected price cuts from GPO programs, intensified competition, and stricter regulatory measures [24] This summary encapsulates the key points discussed during the expert call regarding the current state and future outlook of China's ophthalmology market, highlighting both opportunities and challenges within the industry.